Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO) (TREVO)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01088672|
Recruitment Status : Completed
First Posted : March 17, 2010
Results First Posted : July 17, 2015
Last Update Posted : July 17, 2015
To determine the revascularization rate of the CE-marked Trevo device in large vessel occlusions in ischemic stroke patients.
- Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro interventional procedure.
|Condition or disease||Intervention/treatment||Phase|
|Ischemic Stroke||Procedure: Mechanical Thrombectomy||Phase 4|
- Clinical outcomes at 90 days
- Mortality at 90 days
- Device-related serious adverse events (DRSAEs)
- Symptomatic ICH rate within 24 (-6/+12) hours post-procedure
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||60 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Thrombectomy REvascularization of Large Vessel Occlusions in Acute Ischemic Stroke (TREVO)|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||August 2011|
|Actual Study Completion Date :||November 2011|
Acute Ischemic Stroke
Single arm post market surveillance study for CE marked mechanical thrombectomy device, Trevo retriever for treatment of eligible patients experiencing acute ischemic stroke Mechanical thrombectomy intervention for all subjects in Acute Ischemic Stroke
Procedure: Mechanical Thrombectomy
The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
Other Name: Trevo Procedure
- Revascularization Status [ Time Frame: Post-procedure, immediate=at the end of the procedure, per last angiogram during treatment ]
Revascularization, defined as at least TICI 2a in the vascular territory treated at end of the neuro interventional procedure
Thrombolysis in Cerebral Infarction (TICI) grading system for perfusion (ie blood flow through a vessel) Grade 0:No Perfusion. No antegrade flow beyond the point of occlusion. Grade 1:Penetration With Minimal Perfusion. Grade 2:Partial Perfusion. Grade 2a:Only partial filling (<2/3) of the entire vascular territory is visualized.
Grade 2b:Complete filling of all of the expected vascular territory is visualized, but slower ...
Grade 3:Complete Perfusion. For complete info see Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B et al. (2003) Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke 34: e109-e137.10.1161/01.STR.0000082721.62796.09 PubMed: 12869717[PubMed]
- Clinical Outcomes at 90 Days [ Time Frame: 90-day ]
Good clinical outcome is defined as an modified Rankin Scale (mRS) score of 0-2 at 90 days.
mRS 0-2 indicates functional independence 0 - No symptoms.
- - No significant disability. Able to carry out all usual activities, despite some symptoms.
- - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- - Moderate disability. Requires some help, but able to walk unassisted.
- - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- - Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- - Dead.
- Mortality at 90 Days [ Time Frame: 90-day ]All cause mortality through 90 days post procedure.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01088672
|Christian Doppler Clinic|
|University Hospital Schleswig-Holstein Campus Kiel|
|Technische Universität München|
|Hospital Clínic de Barcelona|
|Barcelona, Spain, 08036|
|Hospital Universitari Germans Trias i Pujols|
|Karolinska University Hospital|
|Principal Investigator:||Nils Wahlgren, MD||Karolinska University Hospital in Solna|
|Principal Investigator:||Olav Jansen, MD||Universitätsklinikum Schleswig-Holstein - Campus Kiel UK S-H|